Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should
Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.
Late Tuesday Shire reported that Takeda had upped its bid to £27.26 in new Takeda shares and £21.75 in cash, coming to £49 a share. That rings up at 0.839 new Takeda shares and $30.33 for each Shire share — or close to $65 billion, with Takeda tacking about $2.5 billion on its previous offer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.